Compound Probiotic Strains for Infectious Pneumonia Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infectious pneumonia, such as antibiotic inhalation, cause significant side effects and there is a need for safer and more effective alternatives, while the use of probiotics in this context is still in its preliminary stages.
Innovation Solution
A compound probiotic comprising Lactobacillus acidophilus LA85 strain (CGMCC No. 1.12735) and Lactobacillus plantarum Lp05 strain (CGMCC No. 23547) is developed, synergistically inhibiting lung infections and reducing inflammation, with a viable count ratio between 1:10 to 10:1 and dosage of at least 1×10^9 CFU/g or CFU/mL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat bacterial pneumonia, then the treatment effect is achieved, but significant side effects occur
Solution Approach 1:
The patent changes the fundamental parameter of treatment approach from conventional antibiotics to probiotics. Specifically, it uses Lactobacillus acidophilus LA85 and Lactobacillus plantarum Lp05 strains to modulate the immune system's response to pneumonia, rather than directly killing bacteria. This parameter change achieves treatment effectiveness while avoiding the harmful side effects associated with antibiotic use
Solution Approach 2:
The patent introduces probiotics as an intermediary substance that mediates between the host immune system and the pathogenic bacteria. The probiotics do not directly eliminate the pathogens but instead regulate immune responses (including reactive oxygen production and inflammatory responses), thereby indirectly achieving treatment效果 while avoiding direct toxic interactions
2Reliability
If single-strain probiotics are used for pneumonia prevention and treatment, then some protective effect is achieved, but the effect is insufficient compared to compound probiotics
Solution Approach 1:
The patent merges two different probiotic strains (Lactobacillus acidophilus LA85 and Lactobacillus plantarum Lp05) into a compound preparation. The combination creates synergistic effects where the strains work together to provide enhanced protection against pneumonia, with the composite probiotic showing significantly better efficacy than either strain alone in preventing and treating infectious pneumonia
Solution Approach 2:
The patent creates a composite probiotic material consisting of multiple bacterial strains with complementary functions. L. acidophilus LA85 and L. plantarum Lp05 have different mechanisms of action that, when combined, provide comprehensive protection against pneumonia while regulating various aspects of immune response, thereby achieving superior treatment effectiveness
Data Source
Figure 1~2
Figure 3
AI summary
The present invention involves a compound probiotic for prevention and treatment of infectious pneumonia and use thereof, and the compound probiotic for prevention and treatment of infectious pneumonia consists of the Lactobacillus acidophilus LA85 strain and the Lactobacillus plantarum Lp05 strain. The two strains can cooperate with each other for mutual promotion, thus synergizing the effect of preventing and treating infectious pneumonia. Compared with the intervention method with only one strain, the compounding of the two strains is significantly more effective in the prevention and treatment of infectious pneumonia under the same dosage. At the same time, both strains are probiotics, so the product is safer and resistance to the product will not be easily generated.